Michael Murphy, Anthony Dowling, Christopher Thien, Emma Priest, Donna Morgan Murray, Santosh Kesari
{"title":"澳大利亚对复发性胶质母细胞瘤患者应用native Voyager®设备的可行性研究","authors":"Michael Murphy, Anthony Dowling, Christopher Thien, Emma Priest, Donna Morgan Murray, Santosh Kesari","doi":"10.2217/cns-2018-0017","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>Evaluation of the Nativis Voyager<sup>®</sup>, an investigational medical device, as monotherapy for recurrent glioblastoma (rGBM).</p><p><strong>Materials & methods: </strong>A total of 15 patients with rGBM were treated with one of two Voyager ultra-low radio frequency energy cognates: A1A or A2HU. Safety and clinical utility were assessed every 2-4 months.</p><p><strong>Results: </strong>Median overall survival was 8.04 months in the A1A arm and 6.89 months in the A2HU arm. No serious adverse events associated with Voyager were reported. No clinically relevant trends were noted in clinical laboratory parameters or physical exams.</p><p><strong>Conclusion: </strong>The data suggest that the Voyager is safe and feasible for the treatment of rGBM.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":"8 1","pages":"CNS31"},"PeriodicalIF":0.0000,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/cns-2018-0017","citationCount":"5","resultStr":"{\"title\":\"A feasibility study of the Nativis Voyager<sup>®</sup> device in patients with recurrent glioblastoma in Australia.\",\"authors\":\"Michael Murphy, Anthony Dowling, Christopher Thien, Emma Priest, Donna Morgan Murray, Santosh Kesari\",\"doi\":\"10.2217/cns-2018-0017\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>Evaluation of the Nativis Voyager<sup>®</sup>, an investigational medical device, as monotherapy for recurrent glioblastoma (rGBM).</p><p><strong>Materials & methods: </strong>A total of 15 patients with rGBM were treated with one of two Voyager ultra-low radio frequency energy cognates: A1A or A2HU. Safety and clinical utility were assessed every 2-4 months.</p><p><strong>Results: </strong>Median overall survival was 8.04 months in the A1A arm and 6.89 months in the A2HU arm. No serious adverse events associated with Voyager were reported. No clinically relevant trends were noted in clinical laboratory parameters or physical exams.</p><p><strong>Conclusion: </strong>The data suggest that the Voyager is safe and feasible for the treatment of rGBM.</p>\",\"PeriodicalId\":10469,\"journal\":{\"name\":\"CNS Oncology\",\"volume\":\"8 1\",\"pages\":\"CNS31\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2217/cns-2018-0017\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"CNS Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/cns-2018-0017\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2019/2/7 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/cns-2018-0017","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/2/7 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
A feasibility study of the Nativis Voyager® device in patients with recurrent glioblastoma in Australia.
Aim: Evaluation of the Nativis Voyager®, an investigational medical device, as monotherapy for recurrent glioblastoma (rGBM).
Materials & methods: A total of 15 patients with rGBM were treated with one of two Voyager ultra-low radio frequency energy cognates: A1A or A2HU. Safety and clinical utility were assessed every 2-4 months.
Results: Median overall survival was 8.04 months in the A1A arm and 6.89 months in the A2HU arm. No serious adverse events associated with Voyager were reported. No clinically relevant trends were noted in clinical laboratory parameters or physical exams.
Conclusion: The data suggest that the Voyager is safe and feasible for the treatment of rGBM.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
